A neoadjuvant, phase II trial demonstrates efficacy and tolerability of Talimogene laherparepvec in cutaneous basal cell carcinoma (NeoBCC trial)
RNA-seq (gene expression) · human · 12 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Basal cell carcinomaThis series is part of our curated briefing on it.
- Samples
- 12 samples
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial)Nature cancer · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE268728_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1118322. Searching any of these in the dataset finder brings you back here.
The grouping that defines any comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Sample titles run NeoBCC04 … NeoBCC18 and carry no group information.
- GSM8297785 NeoBCC04
- GSM8297786 NeoBCC05
- GSM8297787 NeoBCC06
- GSM8297788 NeoBCC07
- GSM8297789 NeoBCC08
- GSM8297790 NeoBCC10
- GSM8297791 NeoBCC11
- GSM8297792 NeoBCC12
- GSM8297793 NeoBCC14
- GSM8297794 NeoBCC15
- GSM8297795 NeoBCC17
- GSM8297796 NeoBCC18
- GSE269601 COL10A1 expression distinguishes a subset of cancer-associated fibroblasts present in the stroma of high-risk basal cell carcinoma 21 samples same disease briefing
- GSE93797 Distinct driver genes and the expression of Hedgehog defines morphoeic basal cell carcinoma 12 samples same disease briefing
- GSE266665 Investigating transcriptional programs regulating invasion in basal cell carcinoma 6 samples same disease briefing
- GSE337786 Integrated multi-omics reveals the cellular and molecular interactions governing the invasive niche in skin cancer II 2 samples same disease briefing
- GSE58377 SMO variants explain the majority of drug resistance in basal cell carcinoma 107 samples same disease briefing
- GSE2959 Genome-wide SNP Microarray Mapping in Basal Cell Carcinomas Unveils Uniparental Disomy as a Key Somatic Event. 28 samples same disease briefing
- GSE281729 Response-Adaptive Surgical Timing in neoadjuvant immunotherapy demonstrates enhanced pathologic treatment response in Head and Neck Squamous Cell Carcinoma 67 samples shares demonstrates, neoadjuvant
- GSE314036 Oncolytic vaccinia virus JX-594 demonstrates subtype-specific efficacy and predictive biomarkers in gastric cancer cell lines 49 samples shares demonstrates, efficacy
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.